Phenylephrine/ketorolac

Phenylephrine/ketorolac, sold under the brand name Omidria, is a combination drug used during cataract surgery^[3] or intraocular lens replacement to prevent intraoperative miosis and to reduce postoperative pain.^[1] It contains phenylephrine and ketorolac.^[1]

Phenylephrine/ketorolac

Combination of
Phenylephrine	Alpha-1 adrenergic receptor agonist
Ketorolac	Nonsteroidal anti-inflammatory
Clinical data
Trade names	Omidria
AHFS/Drugs.com	Monograph
License data	US DailyMed: Phenylephrine_and_ketorolac
Routes of administration	Intraocular
ATC code	S01FB51 (WHO)
Legal status
Legal status	US: ℞-only[1] EU: Rx-only[2] In general: ℞ (Prescription only)
Identifiers
KEGG	D10837

Phenylephrine/ketorolac was approved for medical use in the United States in May 2014,^[4] and in the European Union in July 2015.^[2]